Adverse events: Clinically important effect · persistent aggressive behaviour or agitation in people with schizophrenia
1 finding from 1 review
Self harm ‐ frequency of self harm · persistent aggressive behaviour or agitation in people with schizophrenia
1 finding from 1 review
Mental state: clinically important change in mental state · persistent aggressive behaviour or agitation in people with schizophrenia
1 finding from 1 review
Leaving the study early · persistent aggressive behaviour or agitation in people with schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · persistent aggressive behaviour or agitation in people with schizophrenia
1 finding from 1 review
> 50% reduction in depressive symptoms · people with epilepsy and depression
1 finding from 1 review
Depressive symptoms · people with epilepsy and depression
1 finding from 1 review
Seizure frequency · people with epilepsy and depression
1 finding from 1 review
Treatment withdrawal · people with epilepsy and depression
Sertraline showed no clear difference in withdrawals compared with cognitive behavioural therapy (moderate certainty).
1 finding from 1 review
Quality of life (QOLIE‐89) (1‐ to 3‐month periods) · people with epilepsy and depression
1 finding from 1 review
Adverse effects · people with epilepsy and depression
1 finding from 1 review
> 50% reduction in depressive symptoms · people with epilepsy and depression
1 finding from 1 review
Depressive symptoms · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Seizure frequency · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Treatment withdrawal · people with epilepsy and depression
It is very uncertain whether selective serotonin reuptake inhibitors changes withdrawals compared with cognitive behavioural therapy (very low certainty).
1 finding from 1 review
RR 0.44 [0.05, 3.85]
15 participants
Very low
Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · people with epilepsy and depression
1 finding from 1 review
no estimate extracted
15 participants
Very low
Adverse effects ‐ adverse event profile · people with epilepsy and depression
1 finding from 1 review
Reduction in anxiety symptoms (parent report) post‐treatment · children and adolescents with anxiety disorders
Reduction in anxiety symptoms (parent report) post‐treatment · children and adolescents with anxiety disorders
no estimate extracted
35 studies · 2137 participants
Low
no estimate extracted
30 studies · 1394 participants
Low
no estimate extracted
4 studies · 186 participants
Low
Mental state · schizophrenia
1 finding from 1 review